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ABSTRACT
Vascular changes, including blood brain barrier destabilization, are common pathological features
in multiple sclerosis (MS) lesions. Blood vessels within adult organs are reported to harbor mesen-
chymal stromal cells (MSCs) with phenotypical and functional characteristics similar to pericytes.
We performed an immunohistochemical study of MSCs/pericytes in brain tissue from MS and
healthy persons. Post-mortem brain tissue from patients with early progressive MS (EPMS), late
stage progressive MS (LPMS), and healthy persons were analyzed for the MSC and pericyte
markers CD146, platelet-derived growth factor receptor beta (PDGFRb), CD73, CD271, alpha-
smooth muscle actin, and Ki67. The MS samples included active, chronic active, chronic inactive
lesions, and normal-appearing white matter. MSC and pericyte marker localization were detected
in association with blood vessels, including subendothelial CD1461PDGFRb1Ki671 cells and
CD731CD2711PDGFRb1Ki67– cells within the adventitia and perivascular areas. Both immuno-
stained cell subpopulations were termed mesenchymal perivascular cells (MPCs). Quantitative
analyses of immunostainings showed active lesions containing increased regions of
CD1461PDGFRb1Ki671 and CD731CD2711PDGFRb1Ki67– MPC subpopulations compared to
inactive lesions. Chronic lesions presented with decreased levels of CD1461PDGFRb1Ki671 MPC
cells compared to control tissue. Furthermore, LPMS lesions displayed increased numbers of blood
vessels harboring greatly enlarged CD731CD2711 adventitial and perivascular areas compared
to control and EPMS tissue. In conclusion, we demonstrate the presence of MPC subgroups in
control human brain vasculature, and their phenotypic changes in MS brain, which correlated
with inﬂammation, demyelination and MS disease duration. Our ﬁndings demonstrate that
brain-derived MPCs respond to pathologic mechanisms involved in MS disease progression and
suggest that vessel-targeted therapeutics may beneﬁt patients with progressive MS. STEM CELLS
TRANSLATIONAL MEDICINE 2017;6:1840–1851
SIGNIFICANCE STATEMENT
This immunohistochemical study characterized vascular cells phenotypically similar to pericytes
and mesenchymal stromal cells (MSCs) in brain tissue of multiple sclerosis (MS) and healthy
persons. We found variations in phenotype, distribution, and proliferation of cells co-expressing
markers for MSCs and pericytes that associated with inflammation and MS disease duration. Tis-
sue from long standing MS presented with increased numbers of blood vessels that harbored
expanded perivascular areas of cells staining positive for MSCs/pericyte markers. This is the first
study to show involvement of MSC/pericyte phenotypic changes in MS pathology and highlights
that vessel-targeted treatments may benefit late stage MS.
INTRODUCTION
Multiple sclerosis (MS) is a chronic inﬂammatory
demyelinating disease of the central nervous sys-
tem (CNS). Pathologically, MS presents with the
formation of multiple focal lesions in the CNS that
often develop around blood vessels associated
with breakdown of the blood-brain barrier (BBB),
inﬂammatory cells, demyelination, axonal dam-
age, and glial scarring [1]. The BBB, including
specialized endothelial cell tight junctions in con-
junction with pericytes, provides a highly protec-
tive barrier under healthy conditions [2, 3]. A
signiﬁcant dysregulation of the BBB associated
with lymphocyte recruitment into the CNS repre-
sents a crucial event in MS disease pathogenesis
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[4]. Prominent vascular changes in MS were observed in early
neuropathological reports [5], and recently angiogenesis and
increased blood vessel density have been reported in MS cerebral
white matter [6]. Neuronal tissues, such as the brain, are recog-
nized to possess the highest density of pericytes surrounding
blood vessels in the body [5, 6]. Pericyte depletion studies have
revealed key functions in the regulation of BBB integrity and previ-
ous studies demonstrate an important role for pericytes in immu-
nological responses and repair mechanisms in the CNS [3, 7–9]. In
addition, pericytes have been reported to possess multipotent
potential, differentiating down the mesenchymal lineages in vitro
[10–12]. Recent reports have suggested that mesenchymal stro-
mal cells (MSCs) may represent a subclass of pericytes following
their identiﬁcation in the perivascular tissue of almost all organs
of the human body, including the adult brain [13–15]. In vitro,
MSCs, in addition to their multipotency are characterized by their
capacity to exert strong immunosuppressive and trophic proper-
ties, mainly by the secretion of soluble factors [16]. Consequently,
in vitro expanded MSCs have been used experimentally as an anti-
inﬂammatory cell-based therapy for various diseases, including
MS [17, 18]. A large number of in vitro studies have described the
immunoregulatory and regenerative effects mediated by MSCs.
Indeed evidence from the animal model of MS, experimental
autoimmune encephalomyelitis (EAE), suggests that intravenous
administration of MSCs reduces demyelination, mediates neuro-
protection, and diminishes CNS leukocyte inﬁltration [19, 20].
However, knowledge is limited regarding the biological relevance
of in vivo MSCs in the human CNS, and detailed studies exploring
MSCs in post-mortem brain tissue has not been performed. In
vitro, a molecular signature consisting of positive expression for
CD70, CD90, and CD105 but absence of CD34, CD45, CD14,
CD116, CD796, CD19, and HLA-DR deﬁnes culture-expanded
MSCs [21]. At present, no speciﬁc marker or marker panel has
been established to determine true in vivo MSCs within human
tissues. In addition, pericytes lack a single speciﬁc marker and are
usually identiﬁed by a combination of surface markers, such as
melanoma cell adhesion molecule (CD146), platelet-derived
growth factor receptor beta (PDGFRb, alpha-smooth muscle actin
(a-SMA), and chondroitin sulfate proteoglycan 4 (NG2), and their
anatomical location [3, 13, 22, 23]. However, marker expression is
dynamic and depends on the developmental stage, tissue origin,
and in vivo/in vitro milieu [24]. Since MSCs have similarities with
pericytes, it has been argued that the pericyte may be the true in
vivo equivalent to the in vitro MSC phenotype [13].
In view of the importance of pericytes in maintaining the integ-
rity of the BBB, and the immunoregulatory and regenerative prop-
erties of MSCs and pericytes, we hypothesized that the phenotype,
activity, and distribution of vascular cells resembling MSCs and/or
pericytes, herein referred to as mesenchymal perivascular cells
(MPCs), may be altered with disease activity in MS. To this end, we
analyzed MS brain tissue from early stage progressive MS (EPMS;
disease duration<10 years) in comparison with late stage progres-
sive MS (LPMS; disease duration>17 years) and healthy control
brain tissue. Using an array of MSC and pericyte markers we identi-
ﬁed two MPC populations associated with vessels in both MS and
healthy control brain tissue. Immunoreactivity of MSC and pericyte
markers, in addition to proliferative activity were signiﬁcantly
altered between EPMS and LPMS, and varied between MS lesions
with different inﬂammatory and demyelinating activity. Our ﬁnd-
ings suggest that brain MPCs associated with blood vessel walls
respond to disease processes in MS lesions. Increased
understanding of the localization of MPCs in the brain of MS and
healthy tissues will advance our knowledge about disease speciﬁc
molecular and cellular changes and may provide new insights into
the development of vessel-targeted therapies for MS patients.
MATERIALS AND METHODS
Ethical Considerations and Permissions
Procedures involving human participants were in accordance with
the ethical standards of the Regional Ethics Review Board, Stock-
holm, (Dnr: 2014/822–31/4), and the University of Turku, Finland
(ETML: 14/1803/2016), within the 1964 Helsinki Declaration and
its amendments. For this type of study formal consent was not
required. Samples were also provided by the NeuroResource tis-
sue bank, University College London (UCL) Institute of Neurology,
London, England. (NR LB 06–2015), with informed consent docu-
mentation approved by NHS London Research Ethics Committees,
and tissue samples stored under a Licence from the U.K. Human
Tissue Authority (HTA).
Patient Material
Post-mortem formalin-ﬁxed parafﬁn embedded (FFPE) brain
blocks from EPMS patients (6 secondary progressive MS, SPMS),
aged 40 years (range 29–52 years) with disease duration <10
years (mean 7.5 years, range 7–10 years) were provided by the
NeuroResource tissue bank, UCL Institute of Neurology. FFPE
LPMS patients (8 SPMS and 4 primary progressive, PPMS), aged
60 years (range 40–85 years) with disease duration >17 years
(mean 33 years, range 17–40 years) were provided by the Depart-
ment of Neuropathology, University of Turku. MS cases were
selected retrospectively based on clinical and neuropathological
diagnoses. Overall 48 MS tissue blocks from periventricular areas,
subcortical white matter regions of the frontal lobe, parietal lobe
and occipital lobe were examined. Post-mortem healthy control
brain tissue, collected by Karolinska Institutet Donatum, included
16 blocks from 8 patients (mean age 43 years, range 22–59 years),
from subcortical white matter of frontal and occipital lobes.
Detailed patient and tissue information are provided in Table 1;
Supporting Information Table 1. All brains have been neuropatho-
logically screened to exclude confounding pathologies. Dissected
brain tissues were ﬁxed in 4% (wt/vol) formalin, dehydrated, and
embedded in parafﬁn. Four micrometer thin sections of MS or
healthy tissue were mounted on Superfrost Plus slides (Menzel-
Gl€aser, Braunschweig, Germany, http://www.thermoﬁsher.com/
de/de/home.html). Sections were deparafﬁnized in xylene and
rehydrated through a graded series of alcohols prior to subse-
quent analysis.
Routine Pathological Analyses and Classification of MS
Tissue
Sections were routinely stained with Mayer’s hematoxylin and
eosin and Luxol fast blue using the Ventana HE 600 System (Ven-
tana Medical Systems, Roche Group, Tucson, http://www.ventana.
com). An antibody targeted against CD68 (Supporting Information
Table 2) was stained using the BenchMark XT (Roche Group) auto-
matic stainer system at the Department of Pathology, University
of Turku. CD4, CD8, and myelin basic protein (MBP; Supporting
Information Table 2) stainings were performed as outlined below.
Sections were digitalized on a 3D Histech Midi Scanner System
(Histolab Products AB, Gothenburg, Sweden). Histological ﬁndings
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in each section were examined by three experts and lesions classi-
ﬁed as active, chronic active and chronic inactive as described below.
Macroscopically normal-appearing white matter (NAWM) was
deﬁned by localization at least 1 cm from the visible lesion edge.
Immunohistochemical Staining
The immunohistochemical protocol was adapted from Sugars
et al. [25]. Rehydrated sections were pretreated according to the
parameters described in Supporting Information Table 2 for the
respective antibodies. Sections were rinsed in Tris buffered saline
(50 mM Tris, 150 mM sodium chloride, pH 7.6, with 0.01%
(vol/vol) Tween 20 (TBST; Sigma Aldrich, Stockholm, Sweden,
http://www.sigmaaldrich.com). All sections were treated with 3%
(vol/vol) hydrogen peroxide for 5 minutes at room temperature.
Nonspeciﬁc binding was blocked using 10% (vol/vol) normal rabbit
or goat serum (DAKO, Glostrup, Denmark, http://www.agilent.
com), 0.3% (vol/vol) Triton-X-100 (Sigma), and 0.1% (wt/vol) cold
water ﬁsh gelatin (Sigma) for 1 hour at room temperature, fol-
lowed by incubation with the corresponding primary antibody
(Supporting Information Table 2) prepared in 4% (vol/vol) normal
serum at 48C overnight. Control experiments were performed
with either the corresponding IgG isotype (Vector Laboratories
Ltd., Peterborough, U.K., https://vectorlabs.com/uk/7) or with
omission of the primary antibody (Supporting Information Table
2). The sections were rinsed three times in TBST for 5 minutes and
subsequently probed with 1:500 biotinylated secondary antibody
(Vector Laboratories Ltd.), prepared in 4% (vol/vol) normal serum,
for 1 hour at room temperature. Following washing, enhancement
with the ABC Elite Horseradish Peroxidase (HRP) kit (Vector Labo-
ratories Ltd.) was performed according to the manufacturer’s
instructions. Bound antibody was detected using the 3,30-diamino-
benzidine (DAB) substrate (DAKO) for HRP and the signal devel-
oped for an optimized time period. Sections were counterstained
for 10 seconds with Mayer’s Hematoxylin, followed by dehydra-
tion and mounting in Pertex (Histolab Products AB).
Digital Image Analysis of Immunohistochemical Staining
with Complementary Statistical Analyses
All stained slides were scanned and digitalized using the 3D His-
tech Scanner and viewed within the Panoramic Viewer Software
1.15 (3D Histech). Serial sections from the respective antibodies
were aligned using Case Viewer (3D Histech) and multiple ﬁelds of
view (FoV) were taken from annotated regions by one team
member. To standardize the FoV, every image contained at least
Table 1. Demographics of MS patients and healthy persons included within the study
Sample code Gender Age (years) MS Subdiagnosis
MS disease
duration (years)
Death-autopsy
interval Cause of death
EPMS1 F 42 SPMS 10 34 hours Pneumonia
EPMS2 F 37 SPMS 10 24 hours Pneumonia
EPMS3 F 47 SPMS 7 16 hours Myocardial infarction
EPMS4 F 29 SPMS 8 11 hours Pneumonia
EPMS5 M 52 SPMS 7 29 hours Pneumonia
EPMS6 F 29 SPMS 7 14 hours Pneumonia
LPMS1 F 85 SPMS 40 4 day Urosepsis
LPMS2 M 64 PPMS 30 6 days Pneumonia
LPMS3 M 60 PPMS 34 3 days Respiratory failure
LPMS4 F 51 SPMS 33 5 days Pneumonia
LPMS5 F 69 SPMS 39 6 days Choking
LPMS6 F 45 SPMS 24 1 day Breast cancer
LPMS7 M 60 SPMS 36 5 days Pneumonia and sepsis
LPMS8 M 40 PPMS 20 2 days Pneumonia
LPMS9 F 52 SPMS 35 3 days Pneumonia and sepsis
LPMS10 M 81 SPMS 33 2 days Pneumonia
LPMS11 F 51 PPMS 17 4 days Pnemonia
LPMS12 F 73 SPMS 27 1 day Breast cancer
HC1 M 22 n.a n.a 24 hours Undetermined
HC2 M 25 n.a n.a 48 hours Hanging
HC3 M 47 n.a n.a 60 hours Hanging
HC4 M 36 n.a n.a 48 hours Drug intoxication
HC5 F 59 n.a n.a 24 hours GI bleeding
HC6 M 45 n.a n.a 25 hours Pulmonary embolism
HC7 M 54 n.a n.a 63 hours Hanging
HC8 M 55 n.a n.a 58 hours Drug intoxication
Abbreviations: EPMS, early progressive; F, female; GI, gastrointestinal; HC, healthy control; LPMS, late-stage progressive MS; M, male; n.a, not
applicable; PPMS, primary progressive MS; SPMS, secondary progressive MS.
1842 Mesenchymal Perivascular Cells in Multiple Sclerosis
Oc 2017 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
STEM CELLS TRANSLATIONAL MEDICINE
one vessel. Annotated regions were deﬁned within a lesion, in
macroscopically NAWM and healthy tissues. A minimum of 10
FoV were taken from each region at 320 magniﬁcation on a
1,3663 768 sized screen5 6833 706 dots per inch, (dpi)/image.
Quantiﬁcation of immunolocalization of the markers CD73,
CD271, PDGFRb, CD146, and Ki67 was performed using the open-
source CellProﬁler Software version 2 (http://www.cellproﬁler.org)
(representative images of the process are detailed in Fig. 1) [26].
Within the program, workﬂows were established for each respec-
tive antibody. Original FoV were converted to gray scale to allow
segmentation and identiﬁcation of stained objects (colored
objects were arbitrarily assigned) using the programs threshold
algorithms. Filters were applied to include DAB stained region
objects and nuclei, and to exclude anything that may represent
debris. Output images were manually inspected to facilitate opti-
mization of the program settings. Multiple measurements were
made on the segmented identiﬁed objects, including total stained
pixel area and total pixel area per image.
Total stained pixel area/total pixel area was analyzed for each
image across combinations of stage (EPMS and LPMS) and type of
lesion (active, chronic active, chronic inactive, and NAWM) for
each of the markers (CD146, PDGFRb, Ki67, CD73, and CD271)
separately. We used generalized estimating equations with an
independent working correlation matrix to take the potential
intrasubject correlation into account when estimating the stand-
ard errors [27]. We adopted a gamma distribution family with a
log-link, as the total pixel area showed a positive and skewed dis-
tribution in each of the considered groups. The results are
reported as pixel-area fold-change with 95% conﬁdence intervals,
p values <.05 were considered statistically signiﬁcant. All
analyses were performed with Stata version 14 (StataCorp, College
Station, TX, https://www.stata.com/company/).
Quantification of Vessels
Vessel number was quantiﬁed for EPMS and LPMS, including
regions of active, chronic active, chronic inactive and NAWM tis-
sue, in addition to healthy control brain white matter (ﬁve cases).
Serial sections stained with CD31 and a-SMA were digitally
scanned using the 3D Histech Slide Scanner as described above.
FoV representing lesions, NAWM or healthy tissue were identiﬁed
and the number of vessels positive for CD31 and a-SMA manually
counted within the speciﬁed area. The number of capillaries was
determined from the CD311 and a-SMA– population based on
previous ﬁndings reporting negative immunoreactivity of a-SMA
in adult human brain capillaries [24, 28]. All quantiﬁcation studies
were performed by three separate individuals on three separate
occasions under standardized conditions. Statistical signiﬁcance
for the total number of vessels across the stage (EPMS, LPMS, and
healthy) and lesion type (active, chronic active, chronic inactive,
and NAWM) was assessed as above using generalized estimating
equations with an independent working correlation matrix that
again took into consideration potential intra-subject correlation
during the estimation of standard errors. Calculations were
performed with Stata version 14 (Stata Corp) with p values <.05
considered as signiﬁcant.
RESULTS
MS Lesion Characterization
Characterization of demyelinating and inﬂammatory activity of MS
lesions was assessed using hematoxylin and eosin and Luxol Fast
Blue staining, immunolocalization of macrophages/microglia
(CD68) and inﬁltrating lymphocytes (CD4 and CD8), and MBP
Figure 1. Image analysis workﬂow. Quantiﬁcation of mesenchymal stromal cell/pericyte markers was performed using the CellProﬁler image
analysis software, and workﬂows were established for each respective antibody (representative CD146 and CD73 are shown). Fields of view
were taken from the original image (Raw) and using the program threshold algorithms DAB stained regions (DAB regions) and nuclei (Nuclei)
were deﬁned (colored objects were arbitrarily assigned). Pixel area was determined from the colored segments detected in the DAB regions
and nuclei. The images represent individual areas detected with either DAB or nuclei staining. These identiﬁed regions were subsequently over-
laid on the original ﬁeld of view to allow for validation (Overlay). x- and y-axes represent pixel co-ordinates of the original images. Abbreviation:
DAB, 3,30-diaminobenzidine
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(Supporting Information Fig. 1). A total of 14 active lesions, 25
chronic active lesions, 7 chronic inactive lesions, and 12 NAWM
were included in the study. Data on tissue distribution between
EPMS and LPMS is provided in Supporting Information Table 1.
Classiﬁcation of lesions was performed according to published cri-
teria [29]. Active lesions were characterized by indistinct borders
on Luxol Fast Blue staining and abundant lipid-laden CD681 mac-
rophages/microglia (occasionally MBP positive) throughout the
total lesion areas. Chronic active lesions displayed restriction of
CD681 cells to the lesion border. Inactive lesions contained a
hypocellular demyelinated tissue and a sharp demarcated border
from the NAWM. Examination of CD4 and CD8 staining across all
tissues detected lymphocytes in the MS sections in the perivascu-
lar area and occasionally within the parenchyma associated with
active and chronic active lesions.
Detection of Two Separate Populations of MPCs
in MS and Healthy Control Brain Tissue
Immunohistochemical analysis of the MSC markers CD73 (ecto-50-
nucleotidase) and CD271 (p75-neurotrophin receptor), and peri-
cyte markers, PDGFRb and CD146 (also considered an MSC
marker), was performed on all brain tissue blocks. Serial section
staining identiﬁed co-expression of more than one MPC marker
exclusively in the vasculature and perivascular area of the brain
tissue (Fig. 2; Supporting Information Figs. 2, 3). Two separate
MPC populations associated with cerebral vessels were identiﬁed
based on marker expression and vessel wall distribution, in MS
and healthy control tissue. The innermost MPC population with a
sub-endothelial vascular localization, separated from the CD311
endothelial cell layer, displayed positive immunostaining for
CD146 and PDGFRb but not for CD73 and CD271 (Fig. 2; Support-
ing Information Figs. 2, 3). Second, another population deﬁned as
CD731CD2711PDGFRb1 was detected in the adventitia layer and
perivascular tissue (Fig. 2; Supporting Information Figs. 2, 3). Pro-
liferative activity, evidenced by detection of positive Ki67 immuno-
staining, was found within CD1461PDGFRb1 regions but not in
adventitial/perivascular CD731CD2711PDGFRb1 domains in the
corresponding vessels (Fig. 3A; Supporting Information Figs. 2, 3).
In the smallest vessels and capillaries, distinct differences in distri-
bution of the two MPC populations were impossible to visualize
and a codistribution was observed.
Increased Localization of CD1461PDGFRb1 and
CD731CD2711PDGFRb1 was Associated with
Inflammatory and Demyelinating Activity
Digital image analysis of the immunohistochemistry staining’s,
based on measurements of total area occupied by stain, revealed
signiﬁcant differences between healthy control and MS brain tissue,
in addition to signiﬁcant variations between lesions with diverse
pathological classiﬁcation (Fig. 2; Supporting Information Fig. 2,
Table 3). A major pattern in MS was the increased localization of
cells positive for MSC/pericyte markers associated with ongoing
inﬂammation and demyelination (active and chronic active lesions)
compared to inactive lesions. EPMS active lesions had increased
localization of PDGFRb (5-fold, p< .001) and CD73 (2-fold,
p5 .020) compared to chronic inactive lesions. No signiﬁcant
changes in Ki67 were apparent for EPMS between different lesion
types (Fig. 3B; Supporting Information Table 3). In LPMS, active
lesions displayed enhanced positivity for CD146 (8-fold, p< .001),
PDGFRb (3-fold, p< .001), CD73 (4-fold, p< .001), and CD271 (8-
fold, p< .001) compared to inactive lesions (Supporting Information
Table 3). This was reﬂected in the comparison of chronic active
lesions compared to inactive lesions in LPMS (CD146, 5-fold,
p< .001; CD73, 2-fold, p5 .015, and CD271, 5-fold, p< .001,
Figs. 4A, 4C, 4D; Supporting Information Table 3). Ki67 was also
signiﬁcantly increased in active (3-fold, p5 .008) and chronic active
lesions (3-fold, p5 .001) compared to inactive lesions in LPMS
(Fig. 3B; Supporting Information Table 3). In order to investigate
immunogenicity of the two distinct MPC populations and a possible
correlation with inﬂammatory activity, we performed immunohisto-
chemical staining for HLA-DR on MS lesions, NAWM, and healthy
control tissue. HLA-DR positive staining was detected in the adventi-
tia and perivascular CD731CD2711 regions, and not in the suben-
dothelial MPC layer, in active MS lesions of both EPMS and LPMS
and in some immune cells within the vessel areas (Supporting Infor-
mation Fig. 4). MPCs of chronic active, chronic inactive lesions, and
NAWM were negative for HLA-DR immunoreactivity in both EPMS
and LPMS. Little or no detection of HLA-DR was found in MPCs of
the healthy brain tissue (Supporting Information Fig. 4).
Loss of CD1461PDGFRb1MPCs in Chronic Active and
Inactive MS Lesions Compared to Healthy Control
Tissue
Chronic active and chronic inactive lesions obtained from MS sub-
groups (EPMS and LPMS) demonstrated a pronounced decrease
in localization of CD146 and PDGFRb (Figs. 4A, 4B), compared to
healthy control tissue. In EPMS, CD146 decreased 3-fold in active
lesions (p< .01), 11-fold in chronic active (p< .001), and 5-fold in
chronic inactive (p< .001) lesions, while in LPMS chronic inactive
lesions displayed a 6-fold decrease (p< .001) compared to healthy
tissue (Fig. 4A; Supporting Information Table 3). PDGFRb
decreased 4-fold in both chronic active and chronic inactive
lesions from EPMS (p< .001 for both), and 2-fold in chronic active
(p< .001) and chronic inactive (p5 .009) lesions from LPMS
(Fig. 4B), compared to healthy control tissue.
Enlarged CD731CD2711 Adventitial and Perivascular
Domains Across All MS Lesions in LPMS Compared to
Healthy Control Tissue
Vessels within EPMS tissue lesions presented with enlarged
CD731 regions in active (4-fold, p< .001), chronic active (2-fold,
p< .05), and inactive lesions (2-fold, p< .01) compared to healthy
tissue (Fig. 4C; Supporting Information Table 3). This ﬁnding was
even more pronounced in LPMS where a highly signiﬁcant
increase in perivascular CD731CD2711 cells were detected in all
lesions; CD73 was enriched 14-fold (p< .001) in active, 6-fold
(p< .001) in chronic active lesions and 4-fold (p< .001) in chronic
inactive compared to healthy controls, and CD271 increased 20-fold
(p< .001) in active lesions, 11-fold (p< .001) in chronic active
lesions and 2-fold (p< .001) in chronic inactive lesions compared to
healthy tissue (Figs. 4C, 4D; Supporting Information Table 3).
Increased Detection of CD1461PDGFRb1 and
CD731CD2711PDGFRb1MPCs in Cerebral Vessels of
LPMS Compared to EPMS
Comparative analyses between different disease durations (EPMS
and LPMS) were used to assess potential differences in MPC
marker dynamics and proliferative activity in lesions with similar
neuropathological classiﬁcation (Figs. 2 and 4; and Supporting
Information Table 3). LPMS active lesions, evaluated against EPMS
active lesions, contained vascular tissue with increased CD146
(4-fold, p5 .004) and CD73 (3-fold, p< .001) distribution, while
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no changes in PDGFRb localization were apparent. Compared to
EPMS chronic active lesions, LPMS chronic active lesions pre-
sented with a signiﬁcant enhancement of all MSC/pericyte
markers (CD146, 9-fold, p< .001; PDGFRb, 2-fold, p< .001; CD73,
4-fold, p< .001 and CD271, 8-fold, p< .001). Furthermore, in
chronic inactive LPMS lesions an increased localization of PDGFRb
(3-fold, p5 .001) and CD73 (2-fold, p5 .032), but no change in
CD146 and CD271 were detected compared to EPMS (Fig. 4).
Increased proliferation (Ki67) was recorded in both active (5-fold,
p5 .001) and chronic active (3-fold, p< .001) lesions of LPMS
compared to EPMS (Fig. 3B; Supporting Information Table 3).
Changes in MPC Marker Localization and Proliferative
Activity in NAWM Tissue
Vessels within NAWM exhibited a similar pattern of MPC
distribution to that described above including the innermost
Figure 2. Localization of mesenchymal stromal cell (MSC)/pericyte markers in MS and healthy control brain tissue. Immunohistochemical
staining of serial sections for MSC/pericyte markers localized to the perivascular regions in the adult healthy control brain in chronic active
lesions from EPMS and LPMS, as well as healthy tissues (representative images of disease status across all donors). CD73, CD271, and
PDGFRb were found typically within the adventitial layer and perivascular tissue, whereas pericyte markers CD146 and PDGFRb were
localized abluminally to endothelial cells. Scale bars5 20 mm. Abbreviations: EPMS, early progressive MS; LPMS, late stage progressive MS;
PDGFRb, platelet-derived growth factor receptor beta.
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CD1461PDGFRb1Ki671 and the outer CD731CD2711PDGFRb1
Ki67– populations detected in the adventitial layer and perivascu-
lar tissue. Quantitative image analyses revealed major differences
between MS and healthy tissue, and between EPMS and LPMS
MS subgroups (Fig. 4; Supporting Information Figs. 2, 3, and Table
3). NAWM tissue from EPMS was characterized by a pronounced
decrease in the immunolocalization of CD146 (2-fold, p< .001,
PDGFRb (2-fold, p5 .003) and CD271 (11-fold, p< .001), while
Figure 4. Quantiﬁcation of mesenchymal perivascular cells localization by image analysis in early progressive MS (EPMS) and late stage
progressive MS (LPMS). Quantiﬁcation of immunohistochemical staining for mesenchymal stromal cells/pericyte markers using generalized
estimating equations demonstrated signiﬁcant changes in mean pixel area ratio (fold-change) stained between different MS tissue types and
healthy, and demyelinating disease and healthy. A signiﬁcant difference in marker detection between EPMS and LPMS tissues was also
apparent. (A): CD146, (B): PDGFRb, (C): CD73, and (D): CD271. Detailed numbers pertaining to the signiﬁcance can be found in Supporting
Information Table 3. p values a5.001, b5.005, c5.01, and d 5 .05. The dotted line indicates the normalized value (1) of healthy
tissue. Abbreviations: NAWM, normal-appearing white matter; PDGFRb, platelet-derived growth factor receptor beta.
Figure 3. Analysis of cell proliferation using Ki67. (A): Ki67 localization resembled a similar pattern detected for the markers CD146 and
platelet-derived growth factor receptor beta. Scale bar5 20 mm. (B): In early progressive MS (EPMS) quantiﬁcation of Ki67 staining demon-
strated decreased proliferative activity in active lesions and in NAWM compared to healthy tissue (dotted line normalized to 1). Late stage
progressive MS (LPMS) displayed increased proliferative activity in chronic active lesions compared to healthy control tissue.When comparing
LPMS with EPMS it was observed that the proliferative activity was ampliﬁed in active, chronic active and NAWM lesions of LPMS compared
to EPMS. p values a5.001, b5.01, and c5.05. Abbreviation: NAWM, normal-appearing white matter.
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CD73 distribution increased (2-fold, p< .001) compared to
healthy control vessels. Vascular tissues of NAWM obtained from
LPMS demonstrated decreased detection of CD146 (3-fold,
p< .001) but increased localization of CD73 (6-fold, p< .001), but
no change in either PDGFRb or CD271 compared to healthy con-
trol tissue was detected. Ki67 signiﬁcantly decreased in NAWM in
EPMS tissue compared to healthy tissue (3-fold, p< .001),
whereas NAWM of LPMS showed comparable Ki67 levels. How-
ever, comparison of LPMS NAWM against EPMS demonstrated an
increased Ki67 localization (3-fold, p< .001; Fig. 3B; Supporting
Information Table 3) in LPMS.
Amplified Numbers of Blood Vessels in LPMS Tissue
Compared to EPMS and Healthy Control Tissue
Quantiﬁcation and deﬁnition of blood vessel numbers within MS
and healthy brain tissue was assessed by manual counting of the
total number of CD311 and a-SMA1 vessels respectively (Fig.
5A). In EPMS, NAWM, active, and chronic active lesions, a similar
number of CD311 blood vessels were seen when evaluated
against healthy brain tissue (Fig. 5B; Supporting Information Table
3). EPMS chronic inactive lesions demonstrated a reduced number
of CD311 blood vessels compared to healthy control (mean
difference523-fold, p5 .003). By contrast, CD311 vessels in
LPMS were signiﬁcantly increased in active lesions (mean
difference5 7-fold, p< .001), chronic active lesions (mean
difference5 2-fold, p5 .007), and NAWM (mean difference5 6-
fold, p< .001). LPMS inactive lesions displayed comparable levels
of CD311 vessels to that of healthy tissue. A positive correlation
between numbers of capillaries (CD311a-SMA–) and total vessel
numbers was found, supported by the increase in capillaries in
LPMS active lesions (mean difference5 6-fold, p< .001), chronic
active lesions (mean difference5 2-fold, p5 .040), and NAWM
(mean difference5 5-fold, p< .001) compared to healthy
(Fig. 5B; Supporting Information Table 3). EPMS and LPMS chronic
inactive lesions were both found to have a reduced number of
capillaries compared to healthy control (EPMS mean difference5
23-fold, p5 .004; LPMS mean difference523-fold, p5 .005).
DISCUSSION
Current knowledge on regenerative and immunosuppressive prop-
erties of MSCs has been mainly based on in vitro cultures, while
data on the native identity and in vivo function remain sparse (16),
[30]. Within this study, we demonstrate the localization of cells co-
expressing classical MSC and/or pericyte markers in the human
brain, in association with cerebral blood vessels. In line with our
data, previous studies have reported the presence of sub-
populations of vascular cells with features of MSCs/pericytes in
human organs [31, 32]. Studies on muscle, pancreatic, and adipose
tissue have demonstrated two separate vascular MSC progenitors,
including tunica media CD1461a–SMA1CD34–PDGFRb1NG21
pericytes/smooth muscle cells in the microvasculature and adventi-
tial CD341CD146-a-SMA-PDGFRb-NG2- in larger vessels [31]. In
bone marrow, phenotypical differences of perivascular stromal
cells/pericytes have been associated with functional differences in
hematopoietic stem cells (HSC). Arterioles enclosed by NG21-
Nestinbright pericytes have been found associated with quiescent
HSCs, while sinusoids harboring Nestindim LEPR1 (leptin receptor)
stromal cells/pericytes are in contact with proliferating HSC32. In
the present study, we did not observe differences in MPC
Figure 5. Vessel density changes between stages of multiple sclerosis (MS) and MS tissue type compared to healthy controls. (A): Vessels
were detected in the MS and healthy brain tissue using CD31 and a-SMA immunolocalization. Arrows point to capillaries, designated as
CD311a-SMA– vessels. Scale bars5 20 mm. (B): Semiquantiﬁcation of vessels positive for CD31 and a-SMA were manually counted, as
described in the Materials and Methods, and capillaries determined from the subtraction of a-SMA from CD31. Statistical analysis by general-
ized estimating equations demonstrated signiﬁcant differences with respect to the number of total CD311 vessels and capillaries, between
MS tissue type and between EPMS and LPMS with healthy tissue. p values a5.001, b5.005, c5.01 and d5.05. The dotted line
indicates the normalized value (1) of healthy tissue. Abbreviation: a-SMA, alpha-smooth muscle actin.
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proliferative activity between different types of vasculature, but
we observed proliferation only in CD1461PDGFRb1 subendothe-
lial MPCs while the adventitia/perivascular CD731CD2711
PDGFRb1 population were quiescent. The ﬁnding of Ki671 MPCs
in both healthy control and MS tissue was surprising since prolifer-
ative activity of cells in the adult brain has so far mainly been
shown in endogenous neuronal tissue in both healthy and MS [33,
34]. Our ﬁndings are, however, in agreement with Paul et al. who
isolated and cultured proliferating perivascular PDGFRb1Ki671
cells from healthy brain biopsies, demonstrating tri-lineage differ-
entiation capacity and co-expression of typical MSC (CD90, CD73,
CD105, CD29, CD166, and CD49d) and pericyte (PDGFRb, regulator
of G protein signaling 5, CD146, Nestin, a-SMA, and NG2) markers
[14]. Flow cytometric analysis of perivascular cells from brain biop-
sies of persons with epilepsy has also identiﬁed PDGFRb on the
majority of cells, while only sub-fractions were reported to express
a-SMA, CD73, CD146, and NG2 [15]. Another recent study on
stroke tissue from human brains detected the presence of
Nestin1a-SMA1NG21 cells adjacent to the endothelial cell layer,
which after isolation expressed Ki67 and PDGFRb in adherent cell
cultures [35].
One major ﬁnding in the present study was the loss of suben-
dothelial CD1461 and/or PDGFRb1 localization in chronic active
lesions of both EPMS and LPMS, compared to healthy control tis-
sue. This was not associated with reduced blood vessel numbers
since numbers remained unchanged in EPMS and increased in
LPMS. PDGFRb is a tyrosine kinase involved in pericyte recruitment
during angiogenesis [36]. Studies in mice with genetically disrupted
PDGF/PDGRb signaling have shown that decreased PDGFRb immu-
nostaining correlated with a loss of BBB integrity [3]. Reduced
immunolocalization of PDGFRb1 cells in capillaries has also been
detected in human and mouse acute ischemic brain tissue [37].
Considering that CD146 is a cell adhesion molecule, the pro-
nounced loss in sub-endothelial distribution of CD146 and PDGFRb
may indicate detachment of pericytes from endothelial cells,
although this remains to be determined. Consequently, since the
deﬁnition of a pericyte includes endothelial cell attachment, the
present ﬁndings could imply reduced numbers of pericytes [6].
Our results on proliferative activity associated with
CD1461PDGFRb1 cells demonstrate ongoing cell turnover in both
MS and healthy brain tissue. It may be hypothesized that in MS,
CD1461PDGFRb1MPCs change morphology and/or spatial distri-
bution during proliferation as a consequence of the ongoing path-
ological mechanisms and/or the changed milieu, (Fig. 6). G€oritz
et al. recently described PDGFRb1a-SMA– perivascular cells in
mice spinal cord vasculature, which upon injury detached from
the vascular wall and gave rise to stromal cells that migrated to
the injured site where they participated in regeneration and scar-
ring processes [9]. The migrating scar forming cells (“type A peri-
cytes”) were separated from the more abundant desmin1
pericytes in capillaries (“type B pericytes”). These observations are
in agreement with our results demonstrating enlarged areas of
CD731CD2711 cells in the adventitia and perivascular cell layers
in LPMS. We hypothesize that the increase in adventitial/perivas-
cular CD731CD2711 immunostaining represent accumulation of
differentiated CD731CD2711stromal cells (similar to type A peri-
cytes) possibly originating from sub-endothelial CD1461PDGFRb1
MPCs migrating in response to tissue injury.
Independent to the underlying cause, the decrease in
CD1461PDGFRb1 MPCs may contribute to impairments in the
BBB. Subtle leakage across the BBB has been found in chronic
non-active lesions, which may have a role in progressive MS
[38–40]. Interestingly, it was recently shown that inhibition of
PDGFR-a signaling using imatinib mesylate (Gleevec) enhanced
BBB integrity, reduced CNS inﬂammation, and ameliorated experi-
mental autoimmune encephalitis disease, suggesting a potential
clinical application in MS [41]. Furthermore, brain tissue from
mice stroke models displayed loss of PDGFRb1 pericytes together
with the appearance of a new perivascular PDGFRb1CD1051 cell
population [37]. CD105 is a classical marker for culture-expanded
bone marrow-derived MSCs, but was not included in the current
study since it is abundantly expressed by activated endothelial
cells in MS tissue and could obstruct localization of vessel-
associated MSCs [21, 42].
Interestingly, LPMS presented with larger CD731CD2711
adventitial and perivascular regions and increased numbers of
blood vessels in active, chronic active, and NAWM compared to
healthy brain tissue. CD73 is an extracellular enzyme involved in
anti-inﬂammatory immune responses and has been described to
take part in regulation of the BBB [43, 44]. A previous study
detected strong CD73 immunoexpression in CD311 microvascula-
ture in post-mortem MS brain sections [45]. In the present study,
CD73 was detected only occasionally in the endothelial cell layer.
CD271 (low afﬁnity nerve growth factor receptor) is a receptor for
neurotrophins and recognized as a key player in regulation of neu-
ronal cell death and survival but is also involved in immune cell
function and chronic neuroinﬂammation [46–48]. Notably, in line
with our study, perivascular CD2711 stromal cells have been
found to expand in synovial tissues of rheumatoid arthritis
patients [49].
The present detection of enlarged adventitial and perivascular
CD73 and CD271 positive areas with colocalization of unchanged
PDGFRb immunoreactivity in LPMS are interesting in view of
recent reports suggesting that perivascular PDGFRb expressing
cells are involved in organ ﬁbrosis [50]. Traditionally, resident
astroglia were regarded as key effector cells in tissue injury of the
CNS but recent studies indicate that stromal cells, originating from
perivascular ﬁbroblasts and pericytes, are additional contributors
of the ﬁbrotic scar in CNS injury [9, 37, 51]. Our ﬁndings of
enhanced adventitia and perivascular stromal CD73 and CD271
immunoreactivity in LPMS may be associated with pathologic
ﬁbrotic structures that previously have been demonstrated to
accumulate in MS lesions, although this remains to be conﬁrmed
[52].
Although cultured MSCs have been shown to exhibit remark-
able immunosuppressive capabilities, some studies have also
pointed out that the immunoregulatory properties of MSCs may
depend on culture conditions and on local microenvironment
changes [53–55]. If brain MPCs behave in a similar manner to
MSCs, it may be suggested that MPCs in the brain of MS patients
alter their phenotype and/or function in association with inﬂam-
matory activity. The current study of positive immunostaining of
HLA-DR that colocalized with C731CD2711 in active lesions but
not in chronic lesions support this hypothesis. In addition, the
enlarged C731CD2711 perivascular areas in LPMS further indicate
that MPCs undergo phenotypic changes during the disease
course. Additional functional and molecular studies, however, are
warranted to investigate this theory and to unravel the physiologi-
cal relevance of MPCs in healthy and during disease.
The existence of neovascularization in MS has been estab-
lished but timing of angiogenesis and its pathogenic role remains
unclear [56]. In the current study, blood vessel numbers
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signiﬁcantly increased in active, chronic active lesions, and NAWM
of LPMS in contrast to LPMS chronic inactive lesions and EPMS,
which displayed comparable numbers to healthy tissue.
The age of the healthy group matched EPMS tissue but not
LPMS, which may be considered as a limitation in the present
study. Age-related pathologies may have contributed to the strong
vascular changes in LPMS compared to EPMS and healthy [57].
However, the individual proﬁles of each pericyte/MSC marker in
addition to variations between lesions with different pathologies
suggest that factors other than age are involved in the vascular
pathologies presented herein. Since our intention was to examine
disease progression changes, the differences in average age of
Figure 6. Schematic illustration of the dynamic changes in mesenchymal stromal cells (MSC)/pericyte marker localization with lesion type and
multiple sclerosis (MS) disease duration. Schematic representation of vascular and perivascular dynamic changes observed following immunoloc-
alization of MSC/pericyte markers and cell proliferation by Ki67 in MS lesion brain tissues compared to healthy controls. The images also reﬂect
the relative changes in the quantiﬁcation of immunolocalization compared to healthy tissue, demonstrated by arrows and numbers for each
marker (i.e., "5x5 ﬁvefold increase). CD1461PDGFRb1a-SMA1Ki671 staining displayed a subendothelial localization (blue cells), separated from
the CD311 endothelial cell layer (dark pink cells) and basement membrane (dark blue circle), with CD731CD2711PDGFRb1Ki67– staining in the
adventitial and perivascular area (light pink cells). Active lesions in early progressive MS (EPMS) tissues presented with decreased immunolocaliza-
tion of CD146 and Ki67, a similar distribution of PDGFRb and increased CD73 immunostaining compared to healthy control tissue. CD271 immu-
nostaining was not quantiﬁed in EPMS active lesions. EPMS chronic active and chronic inactive lesions both exhibited loss of CD146, and loss of
PDGFRb in chronic active lesions was also seen compared to healthy tissue. CD73 and CD271 were increased in early chronic active but similar in
early inactive lesions compared to healthy. However, late stage progressive MS (LPMS) active lesions presented with enlarged regions of PDGFRb,
CD73, CD271, and Ki67 compared to healthy control tissues. LPMS chronic active and chronic inactive lesions showed loss of CD146 and PDGFRb,
but CD73 and CD271 signiﬁcantly increased in the adventitia and perivascular areas compared to healthy tissue. Ki67 was signiﬁcantly ampliﬁed
in chronic active lesions but unchanged in chronic inactive lesions of LPMS compared to healthy tissue. CD31 and a-SMA immunostainings were
not quantiﬁed (na5 not applicable). Abbreviations: a-SMA, alpha-smooth muscle actin; PDGFRb, platelet-derived growth factor receptor beta.
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patients in the two MS groups were difﬁcult to avoid. Age-related
changes in the brains of older progressive MS patients have previ-
ously been recognized as potential contributors to the progression
of disease [58].
The mismatch in cause of death between MS cases and healthy
donors is a limitation of the study. However, as our study focused
on cerebral blood vessels, control subjects and MS patients with a
cause of death related to cardiovascular disease were excluded. The
detailed neuropathological examination of the healthy control
brains had demonstrated that signs of inﬂammation or vascular
abnormalities were absent and helped to avoid other pathologies
as confounding factors. The descriptive nature of the current study
does not allow for mechanistic conclusions. The relatively small
cohort of MS patients and controls is a limitation of the study. We
did not separate PPMS from SPMS (in the statistical analyses) since
long standing PPMS and SPMS display many clinical and pathologi-
cal similarities [59]. Larger cohorts of patients are needed to better
distinguish differences in MPCs between MS subjects with different
disease types and disease duration. However, the multiple tissue
regions examined in a considerable number of brain sections and
the high number of FoV counted in each region, all contribute to
give a good representation of each tissue type investigated.
CONCLUSION
The current observations of profound cerebral vessel changes
including phenotypic alterations of MPCs in progressive MS, in
addition to the known functional roles for CD146, PDGFRb, CD73,
and CD271 in neuroinﬂammation, suggest that MPCs play a role
in MS pathology and disease progression. Further studies are war-
ranted to explore the molecular mechanisms involved in the origin
of new MPCs and their functions during disease in order to iden-
tify new vessel-targeted treatments in progressive MS.
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